CHICAGO--(BUSINESS WIRE)--Vigeo Therapeutics, a clinical-stage biopharmaceutical company developing novel therapeutics to reprogram the tumor immune microenvironment (TIME), announced that preliminary data from its Phase 1 open label trial of VT1021 in patients with advanced solid tumors, will be presented tomorrow, June 1st from 8:00 am to 11:00 am CT at the American Society of Clinical Oncology (ASCO) annual meeting being held May 31 – June 4, 2019 in Chicago.
Vigeo is developing therapies that target the TIME via the induction of thrombospondin-1(Tsp-1) by replicating the biological activity of prosaposin (Psap). Tsp-1 is a naturally occurring potent anti-tumorigenic protein that has been shown to reprogram the TIME and block tumor growth and progression.
“We believe that by reprogramming the TIME, we can significantly improve the outcomes of cancer treatments,” said Jing Watnick, Ph.D., M.B.A., chief executive officer of Vigeo. “Emerging clinical data continue to suggest that Vigeo’s VT1021, targeting the tumor microenvironment, is safe and well tolerated and has significant potential in hard-to-treat cancers,” she added.
VT1021 in Patients with Advanced Solid Tumors
Dose
escalation phase of first in human study with VT1021 is ongoing. Through
the first six dose levels tested, VT1021 has been shown to be safe and
well tolerated with no serious drug related adverse events. Enrollment
for expansion cohorts in specific tumor types is expected to be
initiated in the third quarter of 2019.
“The mechanism of action of VT1021 is quite unique,” said Gregory Berk MD, chief medical officer of Vigeo. “The molecule has demonstrated an excellent safety profile and PK/PD properties, and is well positioned to be an effective single agent therapy, as well as an ideal partner for standard of care therapies in various oncology indications.”
Presentation
Title: A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients with Advanced Solid Tumors
Date & Time: Saturday June 1, 2019 from 8:00 am – 11:00 am CT
Abstract Session: Developmental Therapeutics and Tumor Biology
Abstract: TPS3158
Location: Board #144a
Presenter: Michael Cieslewicz, PhD, Vice President for Project Management and Operations, Vigeo
About VT1021
Vigeo’s lead molecule, VT1021, is a small
peptide agent derived from Psap, that triggers Tsp-1 production, which
reprograms the tumor microenvironment and makes it inhospitable for
tumor growth to occur. Pre-clinical results have demonstrated that
VT1021, when administered systemically, can cause tumor regression in
animal models at both the primary and metastatic sites. VT1021 is
currently being evaluated in a Phase 1, open label, multicenter trial
that assesses the drug’s safety, tolerability, and preliminary
anti-tumor efficacy. The trial’s dose escalation phase was launched in
late 2017, and the expansion phase will initiate in 3rd
quarter of 2019. An interim readout is expected in the second half of
2020.
About Vigeo Therapeutics
Vigeo, based in Cambridge MA, is a
clinical-stage biopharmaceutical company committed to developing novel
therapeutics to effectively treat multiple types of cancer and improve
the lives of patients. The company is building a first-in-class drug
discovery pipeline that reprograms the tumor immune microenvironment
(TIME) and is the first, and only, company developing therapies designed
to stimulate Tsp-1 expression by replicating the biological activity of
prosaposin (Psap). For more information please visit www.vigeotherapeutics.com.
